EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

5-(Benzofuran-2-yl)-3-(2-chloro-4-fluorobenzyl)-1,3,4-oxadiazol-2(3H)-one (GM-90663) Alleviates Dravet Syndrome via Inhibiting Monoamine Oxidase Activity

Kyu-Seok Hwang iD, Se Hwan Ahn, Yuji Son iD, Seong Soon Kim iD, Dae-Seop Shin iD, Jung Yoon Yang, Chong Hak Chae, Michiko Nakamura, Il-Sung Jang, Gahyeon Kim, Dong Gun Kim, Pyeongkeun Kim iD und 5 weitere

Molecules · 01.05.2026 · 31 (9) · 1511

DOI: 10.3390/molecules31091511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 01.05.2026. Verfasst von Kyu-Seok Hwang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea. Hauptthemen laut MEDLINE: Monoamine Oxidase, Epilepsies, Myoclonic, Monoamine Oxidase Inhibitors, Oxadiazoles. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea government, Ministry of Trade, Industry & Energy, National Research Council of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dravet syndrome (DS) is a severe, catastrophic childhood epilepsy predominantly caused by loss-of-function mutations in the SCN1A gene, which encodes the voltage-gated sodium channel Nav1.1. In this study, we evaluated the therapeutic potential of 5-(Benzofuran-2-yl)-3-(2-chloro-4-fluorobenzyl)-1,3,4-oxadiazol-2(3H)-one (GM-90663), a novel small molecule designed to address the complex pathophysiology of DS. Using scn1lab knockout (KO) zebrafish larvae—a robust vertebrate model for DS—we demonstrated that GM-90663 significantly alleviates seizure-like behavioral movements and rescues deficit in cognitive-like functions. Whole-cell patch-clamp recordings in hippocampal slices revealed that GM-90663 modulates voltage-gated Na+ channel kinetics; specifically, it suppresses slow ramp-induced currents, thereby effectively attenuating neuronal hyperexcitability. Furthermore, neurochemical profiling indicated that GM-90663 treatment leads to a marked increase in endogenous serotonin (5-HT) levels in both wild-type and KO larvae. Molecular docking simulations and subsequent in vitro enzymatic assays confirmed that this elevation in serotonin is mediated through the potent inhibition of monoamine oxidase (MAO) activity. Collectively, our findings suggest that GM-90663 exerts its anti-seizure effects through a synergistic dual mechanism—stabilizing sodium channel conductance and elevating serotonergic activity—positioning it as a promising multi-target candidate for the treatment of DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoamine OxidaseEpilepsies, MyoclonicMonoamine Oxidase InhibitorsOxadiazolesAnimalsZebrafishMolecular Docking SimulationNAV1.1 Voltage-Gated Sodium ChannelDisease Models, AnimalHippocampusHumans

Stichwörter der Autor:innen

Dravet syndromeSCN1Amonoamine oxidasetreatmentzebrafish

Substanzen

Monoamine OxidaseMonoamine Oxidase InhibitorsOxadiazolesNAV1.1 Voltage-Gated Sodium Channel

Autor:innen und Institutionen

  • Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
  • Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
  • Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Republic of Korea.
  • Brain Science & Engineering Institute, Kyungpook National University, Daegu 41940, Republic of Korea.
  • Department of Medical Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea.
  • JD Bioscience Inc., 208 Cheomdan-dwagiro, Buk-gu, Gwangju 61011, Republic of Korea.

ORCID-Profile: Kyu-Seok Hwang, Yuji Son, Seong Soon Kim, Dae-Seop Shin, Pyeongkeun Kim, Hohjai Lee, Jin Hee Ahn

Förderung

  • Korea government
  • Ministry of Trade, Industry & Energy
  • National Research Council of Science and Technology

Zitieren

APA

Hwang, K. S., Ahn, S. H., Son, Y., Kim, S. S., Shin, D. S., Yang, J. Y., Chae, C. H., Nakamura, M., Jang, I. S., Kim, G., Kim, D. G., Kim, P., Heo, Y., Bae, S., Lee, H., Ahn, J. H., & Bae, M. A. (2026). 5-(Benzofuran-2-yl)-3-(2-chloro-4-fluorobenzyl)-1,3,4-oxadiazol-2(3H)-one (GM-90663) Alleviates Dravet Syndrome via Inhibiting Monoamine Oxidase Activity. Molecules, 31(9), 1511. https://doi.org/10.3390/molecules31091511

Vancouver

Hwang KS, Ahn SH, Son Y, Kim SS, Shin DS, Yang JY, et al. 5-(Benzofuran-2-yl)-3-(2-chloro-4-fluorobenzyl)-1,3,4-oxadiazol-2(3H)-one (GM-90663) Alleviates Dravet Syndrome via Inhibiting Monoamine Oxidase Activity. Molecules. 2026;31(9):1511. doi:10.3390/molecules31091511

BibTeX
@article{Hwang2026,
  author = {Hwang, Kyu-Seok and Ahn, Se Hwan and Son, Yuji and Kim, Seong Soon and Shin, Dae-Seop and Yang, Jung Yoon and Chae, Chong Hak and Nakamura, Michiko and Jang, Il-Sung and Kim, Gahyeon and Kim, Dong Gun and Kim, Pyeongkeun and Heo, Yerim and Bae, Sunjae and Lee, Hohjai and Ahn, Jin Hee and Bae, Myung Ae},
  title = {5-(Benzofuran-2-yl)-3-(2-chloro-4-fluorobenzyl)-1,3,4-oxadiazol-2(3H)-one (GM-90663) Alleviates Dravet Syndrome via Inhibiting Monoamine Oxidase Activity},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {9},
  pages = {1511},
  doi = {10.3390/molecules31091511}
}
Kostenlos starten →